Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KMT2A | Q03164 | 1/20 | 0.37 |
| ▸ | RPS6KB1 | P23443 | 3/20 | 0.36 |
| ▸ | CNR1 | P21554 | 1/20 | 0.35 |
| ▸ | CCNA2 | P20248 | 3/20 | 0.34 |
| ▸ | CDK2 | P24941 | 3/20 | 0.34 |
| ▸ | MAPK1 | P28482 | 3/20 | 0.34 |
| ▸ | MAPK3 | P27361 | 1/20 | 0.34 |
| ▸ | ROCK2 | O75116 | 3/20 | 0.33 |
| ▸ | DGAT1 | O75907 | 1/20 | 0.33 |
| ▸ | ADORA2A | P29274 | 1/20 | 0.33 |
| ▸ | ADORA1 | P30542 | 1/20 | 0.33 |
| ▸ | GRK2 | P25098 | 1/20 | 0.33 |
| ▸ | GRK5 | P34947 | 1/20 | 0.33 |
| ▸ | GRK1 | Q15835 | 1/20 | 0.33 |
| ▸ | CCNK | O75909 | 2/20 | 0.32 |
| ▸ | CDK7 | P50613 | 2/20 | 0.32 |
| ▸ | CCNH | P51946 | 2/20 | 0.32 |
| ▸ | MNAT1 | P51948 | 2/20 | 0.32 |
| ▸ | CDK12 | Q9NYV4 | 2/20 | 0.32 |
| ▸ | BRAF | P15056 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL21150830 | 0.81 | KMT2A (0.40) | KMT2ARPS6KB1CNR1CCNA2CDK2 | |
| SCHEMBL24974628 | 0.81 | GSK3B (0.36) | RPS6KB1CCNA2CDK2MAPK1ROCK2 | |
| SCHEMBL21150766 | 0.76 | EGLN1 (0.35) | RPS6KB1CDK2MAPK1ROCK2 | |
| SCHEMBL21150821 | 0.74 | DCUN1D1 (0.41) | KMT2A | |
| SCHEMBL21151173 | 0.66 | TACR1 (0.47) | KMT2A | |
| SCHEMBL21150803 | 0.62 | KMT2A (0.64) | KMT2ACNR1MAPK1 | |
| SCHEMBL5494066 | 0.62 | ACHE (0.48) | KMT2A | |
| SCHEMBL5497416 | 0.60 | CXCR4 (0.49) | CNR1ROCK2 | |
| SCHEMBL21150801 | 0.60 | L3MBTL1 (0.54) | KMT2A | |
| SCHEMBL13879509 | 0.58 | KMT2A (0.91) | KMT2AMAPK1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11572370-B2 | CD16A binding agents and uses thereof | BIOHAVEN THERAPEUTICS LTD. (US) | 2023-02-07 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11572370-B2 | CD16A binding agents and uses thereof | FCGR1A, FCGR2A, FCGR3B | KMT2A 499/4885RPS6KB1 3049/4885CNR1 813/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.